Compare GMM & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GMM | NOTV |
|---|---|---|
| Founded | 2017 | 1974 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 12.4M |
| IPO Year | 2022 | 1997 |
| Metric | GMM | NOTV |
|---|---|---|
| Price | $1.19 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 174.1K | ★ 534.6K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $0.94 | $0.25 |
| 52 Week High | $4.75 | $3.35 |
| Indicator | GMM | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 35.87 |
| Support Level | $1.04 | $0.25 |
| Resistance Level | $3.18 | $0.65 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 20.99 | 36.86 |
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital asset development for the metaverse industry. The Company leverages its proprietary Mofy Lab technology platform, which integrates three-dimensional (3D) reconstruction technology and artificial intelligence (AI) interactive technology, to create high-definition virtual versions of physical world objects, including humans, animals, and scenes. It provides comprehensive technology solutions to support virtual content production for use across movies, television series, animation, advertising, and gaming. The Company operates through Virtual Technology Services, which generates the majority of revenue, and Digital Asset Development and others.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.